Emily Lo, MD
Otolaryngology · Noblesville, INNPI 1326365024
Payments from drug & device makers
Across 54 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$212
- Acclarent, Inc$116
- GSK$83
- Aerin Medical Inc.$58
- Regeneron Healthcare Solutions, Inc.$54
- Sanofi$50
- plus $420 from 17 others
What the payments were for
- Consulting fees$505%
- Food & beverage$94295%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 15 | $212 |
| Acclarent, Inc | 5 | $116 |
| GSK | 3 | $83 |
| Aerin Medical Inc. | 2 | $58 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Sanofi | 2 | $50 |
| Pacira Therapeutics, Inc. | 2 | $49 |
| Hologic Sales And Service, LLC | 1 | $48 |
| Amgen | 3 | $43 |
| AstraZeneca | 2 | $32 |
| UCB, Inc. | 2 | $31 |
| Kaleo, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Banner Life Sciences, LLC | 1 | $24 |
| Argenx US, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $14 |
| Medtronic | 1 | $14 |
| Baudax Bio Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$992 in reported general payments places this provider in the 40th percentile of 193 otolaryngology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 47 | $160 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Noblesville
- Matthew BrunsNoblesville$15K
- Sydney HarmonNoblesville$5K
- Michael AgostinoNoblesville$3K
- Scott PhillipsCarmel$2.2M
- Joshua GreeneAnderson$1.1M
- Venkata KakarlapudiNew Albany$175K
- Colin NeumannNew Albany$135K
- Noah ParkerCarmel$133K
- Tod HuntleyCarmel$124K
- Satyan SreenathIndianapolis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.